Constantinou M, Miner TJ, Vatkevitch JM, et al. - In this pilot study, researchers assessed nivolumab plus low-dose ipilimumab with respect to its safety as well as toxicity in patients with high-risk completely resected melanoma. Participants were 21 patients in total, who were administered ipilimumab, 1 mg/kg every 6 weeks, and nivolumab, 3 mg/kg every 2 weeks, for a total of 24 weeks (4 cycles). Occurrence of grade 3 treatment-related toxicities was seen in ten of 21 (48%) patients, however, no grade 4 or grade 5 toxicities occurred. Grade 3 nonhematologic toxicities rate exceeded the toxicity limits defined by the study. A median follow-up of 41 months was conducted. The 2-year recurrence-free survival and 2-year overall survival was estimated to be 85.7% and 90.5%, respectively. In the light of these observations, experts suggest the likely promising utility of a 6-month course of nivolumab and low-dose ipilimumab as an adjuvant treatment for patients with resected melanoma. Further investigations of this regimen are indicated.